{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:12:33Z","timestamp":1783977153738,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07119-5","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:52:37Z","timestamp":1781538757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of thromboembolic events in patients with polycythaemia vera: a study based on german health claims data"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-7447","authenticated-orcid":false,"given":"Karina C.","family":"Manz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Morouj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Feuerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Ehne\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barnstorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"H\u00f6er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"7119_CR1","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"key":"7119_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"key":"7119_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M et al (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 123:449\u2013458. https:\/\/doi.org\/10.1002\/cncr.30325","journal-title":"Cancer"},{"key":"7119_CR4","unstructured":"Lengfelder E, Baerlocher GM, D\u00f6hner K, Ernst T, Gisslinger H, Grie\u00dfhammer M, Koschmieder S, Petro EP (2023) Polycythaemia Vera (PV)"},{"key":"7119_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","volume":"98","author":"M Griesshammer","year":"2019","unstructured":"Griesshammer M, Kiladjian J-J, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol 98:1071\u20131082. https:\/\/doi.org\/10.1007\/s00277-019-03625-x","journal-title":"Ann Hematol"},{"key":"7119_CR6","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9:e301\u2013e311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1","journal-title":"Lancet Haematol"},{"key":"7119_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larr\u00e1n","year":"2012","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Cervantes F et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119:1363\u20131369. https:\/\/doi.org\/10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"key":"7119_CR8","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/cncr.34195","volume":"128","author":"A Alvarez-Larr\u00e1n","year":"2022","unstructured":"Alvarez-Larr\u00e1n A, Garrote M, Ferrer-Mar\u00edn F et al (2022) Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea. Cancer 128:2441\u20132448. https:\/\/doi.org\/10.1002\/cncr.34195","journal-title":"Cancer"},{"key":"7119_CR9","doi-asserted-by":"publisher","first-page":"106809","DOI":"10.1016\/j.leukres.2022.106809","volume":"115","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Gerds AT, Yu J et al (2022) Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res 115:106809. https:\/\/doi.org\/10.1016\/j.leukres.2022.106809","journal-title":"Leuk Res"},{"key":"7119_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2023-180309","volume":"142","author":"AT Kuykendall","year":"2023","unstructured":"Kuykendall AT, Yacoub A, Reaven N et al (2023) Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera. Blood 142:137. https:\/\/doi.org\/10.1182\/blood-2023-180309","journal-title":"Blood"},{"key":"7119_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00277-025-06192-6","volume":"104","author":"KC Manz","year":"2025","unstructured":"Manz KC, Mocek A, Morouj B et al (2025) Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data. Ann Hematol 104:347\u2013360. https:\/\/doi.org\/10.1007\/s00277-025-06192-6","journal-title":"Ann Hematol"},{"key":"7119_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F et al (2022) Sampling strategy, characteristics and representativeness of the InGef research database. Public Health 206:57\u201362. https:\/\/doi.org\/10.1016\/j.puhe.2022.02.013","journal-title":"Public Health"},{"key":"7119_CR13","unstructured":"Bundesministerium f\u00fcr Gesundheit (2025) ICD codes overview. https:\/\/gesund.bund.de\/en\/icd-code-search. Accessed 11 Nov 2025"},{"key":"7119_CR14","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2025) ATC-Classification. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ATC\/_node.html. Accessed 11 Nov 2025"},{"key":"7119_CR15","unstructured":"Associations of Statutory Health Insurance Physicians (2025) Einheitlicher Bewertungsma\u00dfstab [doctor\u2019s fee scale]. https:\/\/www.kbv.de\/praxis\/abrechnung\/ebm. Accessed 11 Nov 2025"},{"key":"7119_CR16","unstructured":"Bundesministerium f\u00fcr Gesundheit (2025) OPS codes overview. https:\/\/gesund.bund.de\/en\/ops-code-search. Accessed 11 Nov 2025"},{"key":"7119_CR17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G et al (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961\u2013963. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08019.x","journal-title":"Br J Haematol"},{"key":"7119_CR18","doi-asserted-by":"publisher","unstructured":"Alvarez-Larr\u00e1n A, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F et al (2017) Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. 1 102:103\u2013109. https:\/\/doi.org\/10.3324\/haematol.2016.152769","DOI":"10.3324\/haematol.2016.152769"},{"key":"7119_CR19","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1182\/blood.V126.23.5187.5187","volume":"126","author":"RV Boccia","year":"2015","unstructured":"Boccia RV, Stein B, Mesa RA et al (2015) Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study. Blood 126:5187. https:\/\/doi.org\/10.1182\/blood.V126.23.5187.5187","journal-title":"Blood"},{"key":"7119_CR20","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1182\/blood.V126.23.5184.5184","volume":"126","author":"S Fazal","year":"2015","unstructured":"Fazal S, Miller CB, Mascarenhas JO et al (2015) Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States. Blood 126:5184. https:\/\/doi.org\/10.1182\/blood.V126.23.5184.5184","journal-title":"Blood"},{"key":"7119_CR21","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1182\/blood-2021-153221","volume":"138","author":"J Song","year":"2021","unstructured":"Song J, Kim SJ, Thiagarajan P et al (2021) Iron Deficiency in Polycythemia Vera Increases HIF Activity and Transcription of Prothrombotic Genes. Blood 138:2549. https:\/\/doi.org\/10.1182\/blood-2021-153221","journal-title":"Blood"},{"key":"7119_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"7119_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18:88\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(16)30558-7","journal-title":"Lancet Oncol"},{"key":"7119_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Kerguelen A, Hern\u00e1ndez-Boluda JC et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172:786\u2013793. https:\/\/doi.org\/10.1111\/bjh.13886","journal-title":"Br J Haematol"},{"key":"7119_CR25","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 5:e366. https:\/\/doi.org\/10.1038\/bcj.2015.95","journal-title":"Blood Cancer J"},{"key":"7119_CR26","unstructured":"Grie\u00dfhammer M, Al-Ali HK, Baerlocher GM et al (2025) Myelofibrose"},{"key":"7119_CR27","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874\u20131881. https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"key":"7119_CR28","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021\u20133023. https:\/\/doi.org\/10.1182\/blood-2014-07-591610","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07119-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07119-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07119-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:01:45Z","timestamp":1783976505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07119-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7119"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07119-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since all patient-level data in the database are anonymized to comply with German data protections regulations and German federal law, approval of an Ethics Committee was not required. The research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study was funded by Novartis Pharma GmbH. The authors had complete autonomy for the process of designing the study, carrying out the analyses, interpreting the results, and preparing the manuscript. This also includes the full right to publish the results without limitation.AH is an employee of the IGES Institut GmbH, which is a paid consultant to Novartis Pharma GmbH for conducting the study and preparing the manuscript. At the time of this study, KCM was an employee of the IGES Institut GmbH. BM is an employees of the InGef \u2013 Institute for Applied Health Research Berlin GmbH, which was contracted and reimbursed by IGES Institut GmbH for providing the data and carrying out the analyses.MF, RE, IB, and PL are employees of Novartis Pharma GmbH. RE and IB hold stock and\/or stock options of Novartis Pharma AG. HKA received research support from Bristol-Myers Squibb, Incyte, and Novartis, consulting fees from AbbVie, AOP Health, Bristol-Myers Squibb, GSK, Novartis, and Otsuka, advisory board fees from AbbVie, AOP Health, Blueprint, Bristol-Myers Squibb, GSK, and Novartis, and a travel grant from Alexion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since anonymized administrative claims data were used and presented only in aggregate form, informed consent of patients was not required. The pre-existing database did not allow direct identification of patients, and no contact was made with patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}],"article-number":"301"}}